Lannett Co Inc (LCI) 62.28 $LCI Roche (RHHBY) L
Post# of 64074
Posted On: 03/04/2015 6:28:57 PM
Lannett Co Inc (LCI) 62.28 $LCI
Roche (RHHBY) Launches Next-Generation Hepatitis B Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 1:00PM CST
Roche Holding AG (RHHBY) recently announced that it has launched the next-generation viral load assay for Hepatitis B virus (HBV) in markets that accept the CE Mark.
LCI: 62.28 (+0.01), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
Catalent, Inc. (CTLT) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:18AM CST
Catalent, Inc. (CTLT) was a big mover last session, as the company saw its shares rise over 5% on the day.
LCI: 62.28 (+0.01), CTLT: 29.77 (-0.22)
BioLineRx (BLRX) Looks Good: Stock Adds 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 7:51AM CST
BioLineRx, Ltd. (BLRX) was a big mover last session, as the company saw its shares rise almost 16% on the day.
LCI: 62.28 (+0.01), BLRX: 2.84 (+0.25)
Pacira Pharmaceuticals Plunges on FDA's CRL for Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 4:45PM CST
Shares of Pacira Pharmaceuticals, Inc. (PCRX) plunged 19.6% after the company announced the receipt of a CRL from the FDA following a review of its supplemental new drug application (sNDA) for Exparel.
LCI: 62.28 (+0.01), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15), PCRX: 95.39 (+1.45)
Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 1:30PM CST
Positive news flowed in for Actavis plc (ACT) when the EC granted marketing authorization to Xydalba for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
MNK: 116.19 (+1.34), IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09)
Salix Posts Wider-than-Expected Q4 Loss as Sales Slump - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:20AM CST
Salix Pharmaceuticals (SLXP) reported a fourth-quarter 2014 loss of $2.61 per share, substantially wider than the Zacks Consensus Estimate of a loss of 29 cents.
LCI: 62.28 (+0.01), VRX: 203.15 (+0.54), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
Ohr Pharmaceutical (OHRP) Jumps: Stock Moves 27.2% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 7:51AM CST
Ohr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise over 27% on the day.
LCI: 62.28 (+0.01), OHRP: 10.72 (+0.37)
Roche's Avastin Gets Positive Opinion for Cervical Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 4:10PM CST
Roche (RHHBY) announced that the European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the use of Avastin in combination with standard chemotherapy.
LCI: 62.28 (+0.01), ISIS: 70.16 (+1.50), ANIP: 67.18 (+0.32)
Dow Leads As Stocks Pare Gains; Disney, Visa Mark Record Highs
at Investor's Business Daily - Mon Mar 02, 12:56PM CST
Stocks pared their gains in early-afternoon trading as blue chips took the lead. The Nasdaq was back below 5000 after cutting its gain to 0.5% and the S&P 500 to 0.3%. The Dow Jones industrial average extended its advance to 0.6%, as Disney (DIS) and...
LCI: 62.28 (+0.01), V: 273.75 (-1.55), SONC: 33.72 (-0.14), DIS: 105.57 (-0.78), NXPI: 99.47 (+0.74), FSL: 40.36 (-0.14)
3 Pharmaceutical Stocks Set for Massive Earnings Growth in 2015 - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Mar 02, 12:20PM CST
These pharma stocks have seen rising earnings estimates lately and could be poised for growth in 2015.
IHE: 169.91 (+1.29), LCI: 62.28 (+0.01), SCMP: 14.82 (-0.15), BLRX: 2.84 (+0.25)
Keryx Biopharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 11:10AM CST
Keryx Biopharmaceuticals (KERX) reported a loss of 44 cents per share in the fourth quarter of 2014, much wider than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago quarter figure of 21 cents per share.
LCI: 62.28 (+0.01), ISIS: 70.16 (+1.50), ANIP: 67.18 (+0.32), KERX: 13.26 (+0.22)
Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 14.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 7:51AM CST
Aurinia Pharmaceuticals (AUPH) was a big mover last session, as the company saw its shares rise almost 15% on the day.
LCI: 62.28 (+0.01), AUPH: 4.51 (-0.01)
Akorn, Avago Lead IBD 50 Stocks In Earnings Growth
at Investor's Business Daily - Sat Feb 28, 7:02AM CST
The IBD 50 list of top-rated stocks is a prime investing tool to locate companies such as Akorn that have outstanding profit growth. With the latest earnings season winding down, here are the top five IBD 50 stocks ranked by strongest earnings per...
AMBA: 67.49 (+4.44), ELX: 7.98 (unch), GPRO: 43.01 (+2.71), LCI: 62.28 (+0.01), SWKS: 90.15 (+1.41), AKRX: 51.19 (+1.86), AAPL: 128.54 (-0.82), AVGO: 129.40 (+1.18)
Stocks Slip, But Tumi Briefly Clears Buy Point
at Investor's Business Daily - Fri Feb 27, 1:58PM CST
Stocks were lower with an hour to go in Friday's session, as investors weighed a raft of mixed economic data. The Nasdaq was down 0.5%, the Dow Jones industrial average slipped 0.3% and the S&P 500 was down 0.2%. NYSE and Nasdaq volume were tracking...
MNST: 139.54 (-1.15), LCI: 62.28 (+0.01), CHK: 15.49 (-0.71), TUMI: 23.21 (-0.04), IPGP: 97.35 (-0.64)
Strength Seen in ArQule (ARQL): Stock Soars 19.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:25AM CST
ArQule (ARQL) was a big mover last session, with shares rising over 19% on the day.
LCI: 62.28 (+0.01), ARQL: 1.91 (+0.04)
United Therapeutics Beats on Q4 Earnings & Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 9:40AM CST
United Therapeutics (UTHR) beats on fourth quarter 2014 earnings; revenues rise.
LCI: 62.28 (+0.01), ADHD: 7.41 (+0.21), UTHR: 157.33 (-0.41), PETX: 19.65 (+0.48)
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 116.19 (+1.34), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09), EGLT: 15.36 (unch), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08), ABBV: 60.27 (+0.65), TEVA: 56.56 (+0.10), ALKS: 70.80 (-2.00), ACUR: 0.74 (-0.08)
Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 8:36AM CST
Pacira Pharmaceuticals' (PCRX) fourth-quarter net income of 14 cents per share missed the Zacks Consensus Estimate of 19 cents. The company had reported a loss of 36 cents per share in the year-ago quarter
IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), SCMP: 14.82 (-0.15), PCRX: 95.39 (+1.45)
Merck Strikes Deal with NGM to Develop Novel Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 5:05PM CST
Merck (MRK) enters into deal with NGM Pharmaceuticals; To develop, discover and commercialize novel biologic therapies.
LCI: 62.28 (+0.01), ADHD: 7.41 (+0.21), MRK: 57.88 (-0.46), PETX: 19.65 (+0.48)
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 3:13PM CST
Novartis AG (NVS) announced that the FDA has approved its blood cancer drug Farydak (panobinostat or LBH589) capsules.
IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), SCMP: 14.82 (-0.15), NVS: 99.04 (-0.02)
Roche (RHHBY) Launches Next-Generation Hepatitis B Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 1:00PM CST
Roche Holding AG (RHHBY) recently announced that it has launched the next-generation viral load assay for Hepatitis B virus (HBV) in markets that accept the CE Mark.
LCI: 62.28 (+0.01), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
Catalent, Inc. (CTLT) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:18AM CST
Catalent, Inc. (CTLT) was a big mover last session, as the company saw its shares rise over 5% on the day.
LCI: 62.28 (+0.01), CTLT: 29.77 (-0.22)
BioLineRx (BLRX) Looks Good: Stock Adds 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 7:51AM CST
BioLineRx, Ltd. (BLRX) was a big mover last session, as the company saw its shares rise almost 16% on the day.
LCI: 62.28 (+0.01), BLRX: 2.84 (+0.25)
Pacira Pharmaceuticals Plunges on FDA's CRL for Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 4:45PM CST
Shares of Pacira Pharmaceuticals, Inc. (PCRX) plunged 19.6% after the company announced the receipt of a CRL from the FDA following a review of its supplemental new drug application (sNDA) for Exparel.
LCI: 62.28 (+0.01), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15), PCRX: 95.39 (+1.45)
Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 1:30PM CST
Positive news flowed in for Actavis plc (ACT) when the EC granted marketing authorization to Xydalba for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
MNK: 116.19 (+1.34), IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09)
Salix Posts Wider-than-Expected Q4 Loss as Sales Slump - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 9:20AM CST
Salix Pharmaceuticals (SLXP) reported a fourth-quarter 2014 loss of $2.61 per share, substantially wider than the Zacks Consensus Estimate of a loss of 29 cents.
LCI: 62.28 (+0.01), VRX: 203.15 (+0.54), SLXP: 157.13 (+0.63), SCMP: 14.82 (-0.15)
Ohr Pharmaceutical (OHRP) Jumps: Stock Moves 27.2% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 7:51AM CST
Ohr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise over 27% on the day.
LCI: 62.28 (+0.01), OHRP: 10.72 (+0.37)
Roche's Avastin Gets Positive Opinion for Cervical Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 4:10PM CST
Roche (RHHBY) announced that the European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the use of Avastin in combination with standard chemotherapy.
LCI: 62.28 (+0.01), ISIS: 70.16 (+1.50), ANIP: 67.18 (+0.32)
Dow Leads As Stocks Pare Gains; Disney, Visa Mark Record Highs
at Investor's Business Daily - Mon Mar 02, 12:56PM CST
Stocks pared their gains in early-afternoon trading as blue chips took the lead. The Nasdaq was back below 5000 after cutting its gain to 0.5% and the S&P 500 to 0.3%. The Dow Jones industrial average extended its advance to 0.6%, as Disney (DIS) and...
LCI: 62.28 (+0.01), V: 273.75 (-1.55), SONC: 33.72 (-0.14), DIS: 105.57 (-0.78), NXPI: 99.47 (+0.74), FSL: 40.36 (-0.14)
3 Pharmaceutical Stocks Set for Massive Earnings Growth in 2015 - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Mar 02, 12:20PM CST
These pharma stocks have seen rising earnings estimates lately and could be poised for growth in 2015.
IHE: 169.91 (+1.29), LCI: 62.28 (+0.01), SCMP: 14.82 (-0.15), BLRX: 2.84 (+0.25)
Keryx Biopharmaceuticals' Q4 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 11:10AM CST
Keryx Biopharmaceuticals (KERX) reported a loss of 44 cents per share in the fourth quarter of 2014, much wider than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago quarter figure of 21 cents per share.
LCI: 62.28 (+0.01), ISIS: 70.16 (+1.50), ANIP: 67.18 (+0.32), KERX: 13.26 (+0.22)
Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 14.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 7:51AM CST
Aurinia Pharmaceuticals (AUPH) was a big mover last session, as the company saw its shares rise almost 15% on the day.
LCI: 62.28 (+0.01), AUPH: 4.51 (-0.01)
Akorn, Avago Lead IBD 50 Stocks In Earnings Growth
at Investor's Business Daily - Sat Feb 28, 7:02AM CST
The IBD 50 list of top-rated stocks is a prime investing tool to locate companies such as Akorn that have outstanding profit growth. With the latest earnings season winding down, here are the top five IBD 50 stocks ranked by strongest earnings per...
AMBA: 67.49 (+4.44), ELX: 7.98 (unch), GPRO: 43.01 (+2.71), LCI: 62.28 (+0.01), SWKS: 90.15 (+1.41), AKRX: 51.19 (+1.86), AAPL: 128.54 (-0.82), AVGO: 129.40 (+1.18)
Stocks Slip, But Tumi Briefly Clears Buy Point
at Investor's Business Daily - Fri Feb 27, 1:58PM CST
Stocks were lower with an hour to go in Friday's session, as investors weighed a raft of mixed economic data. The Nasdaq was down 0.5%, the Dow Jones industrial average slipped 0.3% and the S&P 500 was down 0.2%. NYSE and Nasdaq volume were tracking...
MNST: 139.54 (-1.15), LCI: 62.28 (+0.01), CHK: 15.49 (-0.71), TUMI: 23.21 (-0.04), IPGP: 97.35 (-0.64)
Strength Seen in ArQule (ARQL): Stock Soars 19.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:25AM CST
ArQule (ARQL) was a big mover last session, with shares rising over 19% on the day.
LCI: 62.28 (+0.01), ARQL: 1.91 (+0.04)
United Therapeutics Beats on Q4 Earnings & Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 9:40AM CST
United Therapeutics (UTHR) beats on fourth quarter 2014 earnings; revenues rise.
LCI: 62.28 (+0.01), ADHD: 7.41 (+0.21), UTHR: 157.33 (-0.41), PETX: 19.65 (+0.48)
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 116.19 (+1.34), LCI: 62.28 (+0.01), ACT: 296.14 (-0.09), EGLT: 15.36 (unch), ZGNX: 1.68 (+0.01), PFE: 34.64 (+0.08), ABBV: 60.27 (+0.65), TEVA: 56.56 (+0.10), ALKS: 70.80 (-2.00), ACUR: 0.74 (-0.08)
Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 8:36AM CST
Pacira Pharmaceuticals' (PCRX) fourth-quarter net income of 14 cents per share missed the Zacks Consensus Estimate of 19 cents. The company had reported a loss of 36 cents per share in the year-ago quarter
IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), SCMP: 14.82 (-0.15), PCRX: 95.39 (+1.45)
Merck Strikes Deal with NGM to Develop Novel Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 5:05PM CST
Merck (MRK) enters into deal with NGM Pharmaceuticals; To develop, discover and commercialize novel biologic therapies.
LCI: 62.28 (+0.01), ADHD: 7.41 (+0.21), MRK: 57.88 (-0.46), PETX: 19.65 (+0.48)
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 3:13PM CST
Novartis AG (NVS) announced that the FDA has approved its blood cancer drug Farydak (panobinostat or LBH589) capsules.
IPXL: 40.40 (+0.47), LCI: 62.28 (+0.01), SCMP: 14.82 (-0.15), NVS: 99.04 (-0.02)
(0)
(0)Scroll down for more posts ▼